@article{db45c6707e67422e801bb99ed1e65b39,
title = "Next-Generation Regimens. The Future of Hepatitis C Virus Therapy",
abstract = "The treatment of chronic hepatitis C virus (HCV) has undergone a period of rapid evolution. The era of combination direct antivirals has led to high rates of sustained viral response (SVR), limited toxicities, and more broad applicability across patient demographics. Even current therapies have their limitations, however, including genotype specificity and variable durations of treatment depending on the presence or absence of cirrhosis. Developing a fixed-duration pangenotypic regimen that can broadly treat all stages of fibrosis with equal rates of SVR in all patients, irrespective of treatment experience, is the goal of future therapies. This article reviews antivirals in development.",
keywords = "Direct-acting antivirals, Genotype 1, Hepatitis C, Resistance-associated variants, Second generation",
author = "John Vizuete and Hope Hubbard and Eric Lawitz",
note = "Funding Information: Disclosures: Dr E. Lawitz has received research and grant support from AbbVie , Achillion Pharmaceuticals , Boehringer Ingelheim , Bristol-Myers Squibb , Gilead Sciences , GlaxoSmithKline , Idenix Pharmaceuticals , Janssen, Merck & Co ., Novartis , Presidio , Roche , Salix , Santaris Pharmaceuticals , Theravance , and Vertex Pharmaceuticals . He has also served as a speaker for AbbVie, Gilead, Janssen, and has provided advisory and consultation services to AbbVie, Achillion Pharmaceuticals, BioCryst, Biotica, Bristol-Myers Squibb, Enanta, Gilead Sciences, Idenix Pharmaceuticals, Janssen, Merck & Co., Novartis, Santaris Pharmaceuticals, Regulus, Theravance, and Vertex Pharmaceuticals. Dr J. Vizuete and Dr H. Hubbard have nothing to disclose. Publisher Copyright: {\textcopyright} 2015 Elsevier Inc. Copyright: Copyright 2015 Elsevier B.V., All rights reserved.",
year = "2015",
month = nov,
doi = "10.1016/j.cld.2015.06.009",
language = "English (US)",
volume = "19",
pages = "707--716",
journal = "Clinics in Liver Disease",
issn = "1089-3261",
publisher = "W.B. Saunders Ltd",
number = "4",
}